Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
about
Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapyPolymeric drug delivery for the treatment of glioblastomaPolifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapyNeurosurgical oncology: advances in operative technologies and adjuncts.Spatial Habitat Features Derived from Multiparametric Magnetic Resonance Imaging Data Are Associated with Molecular Subtype and 12-Month Survival Status in Glioblastoma Multiforme.Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.Low levels of Human Cytomegalovirus Infection in Glioblastoma multiforme associates with patient survival; -a case-control study.Dimethyl sulfoxide (DMSO) as a potential contrast agent for brain tumors.Hyperthermia and chemotherapy using Fe(Salen) nanoparticles might impact glioblastoma treatment.Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study.The future of high-grade glioma: Where we are and where are we going.A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001.Association between body mass index and mortality in patients with glioblastoma mutliformeA multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas.The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival.Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide.Texture Feature Ratios from Relative CBV Maps of Perfusion MRI Are Associated with Patient Survival in Glioblastoma.Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomasSurvival analysis of HDR brachytherapy versus reoperation versus temozolomide alone: a retrospective cohort analysis of recurrent glioblastoma multiforme.Concurrent Chemotherapy of Malignant Glioma in Rats by Using Multidrug-Loaded Biodegradable Nanofibrous Membranes.Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes.The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.Long-term survival after gamma knife radiosurgery in a case of recurrent glioblastoma multiforme: a case report and review of the literature.Encapsulated stem cells for cancer therapy.The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.The role of Gliadel wafers in the treatment of high-grade gliomas.Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas.The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model.Advanced interstitial chemotherapy for treating malignant glioma.Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to the brain by using drug-loaded nanofibrous membranes.Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.Vaccinia virus expressing bone morphogenetic protein-4 in novel glioblastoma orthotopic models facilitates enhanced tumor regression and long-term survival.Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients.Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study.Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice.Expression of cytomegalovirus in glioblastoma multiforme: Myth or reality?
P2860
Q27000814-FFC5C432-39B0-46B4-9AF3-EB72A0535D08Q27010046-D6309501-1582-46C0-928A-D54F64108CFBQ28078486-31CAB8D0-5990-491F-96CF-F4235874F7B3Q30833619-C57958BF-FF20-4C9E-BDDA-6CB4F0682BB6Q30993492-69819B83-0B73-4786-8240-8FA74380790CQ34048935-F15D32C5-079E-4B85-9891-B3B19C5F2D64Q34198365-E2A8E42D-8DB9-4713-A6A3-81D783C55BC8Q34344365-C70A64C4-604F-4B88-A57F-DFDDE6BBE409Q34551625-301ABEAD-3D38-496D-BE8B-832F8688BC71Q34581669-A9E9C66B-56CD-4BFB-9C90-3A410BBD534AQ35114090-87988E6C-5E0C-42FD-B5AB-D9E6AA08BFE8Q35733207-88709142-B8A6-43F2-B309-DD702DE4DCDBQ35853548-2F746161-1DEB-4543-A91F-6AA10B6D378FQ35943928-ADABE5F1-EC22-496A-BF03-B3B6308A974EQ36181979-3A1A6E1A-C6C0-40DD-B45E-44BA8E5E4E57Q36250744-CC686187-DDC1-4567-9851-499ADE9B053CQ36357995-0AF33702-91D2-4CDD-8C49-6FD1431C4256Q36463578-8D716F57-467C-418C-BA8B-44EBB396837AQ36695971-84B20ED0-94A2-4B2A-9B97-152EB1A51FBEQ36730160-DED4EDD3-7D1A-4605-A206-309B8577F417Q37137363-60DB1670-D729-46B7-B1A8-6DE1F5DD0DB5Q37644962-9F9E1F5A-1F55-47FD-AEAD-E57679655D5AQ37846215-6D912406-964A-4785-BA08-CB89A4D3464FQ38006702-B4125EB9-C996-4D25-B669-3CED777D4905Q38090923-16798F67-9F51-4801-ABB1-C806E7C3CFBCQ38093776-ED03D211-74B5-4C80-AC22-0E711E4F0365Q38162925-2ECD6B4E-B82F-4EDC-88FB-D121A40E9B10Q38411351-0BA998E5-78CC-44EF-8202-67ACF289A285Q38546470-C4991A15-D1B6-4091-8C07-B52436E410B6Q38743138-8D133256-983E-4131-A9BE-FCF318292CAAQ38764607-A02D7290-A22C-4049-A4E4-7808ABA791C3Q38849948-DBEA724B-809A-4C57-9CAF-A820D5009D10Q38938545-59268A2F-8060-4661-8327-CDF43385767FQ38957729-A9A8A214-8D0E-4A2F-899B-4EA16FC472FBQ39046974-23C62545-FEAA-4A69-A056-FC9867AEC8FCQ39135169-1525C2AA-F68B-4EBB-869E-97E2226243D3Q39279856-9718B51A-AEC6-4516-8750-E0D7C89A416FQ39468197-35C0EA96-50D7-4419-9BD8-576EE348A5F1Q40150597-5F37A191-6060-4FC0-98A3-EF7826281221Q40841407-364AE87F-04AE-4AC1-86D4-466CABFE641F
P2860
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Overall survival of newly diag ...... ional multiagent chemotherapy.
@ast
Overall survival of newly diag ...... ional multiagent chemotherapy.
@en
type
label
Overall survival of newly diag ...... ional multiagent chemotherapy.
@ast
Overall survival of newly diag ...... ional multiagent chemotherapy.
@en
prefLabel
Overall survival of newly diag ...... ional multiagent chemotherapy.
@ast
Overall survival of newly diag ...... ional multiagent chemotherapy.
@en
P2093
P50
P356
P1433
P1476
Overall survival of newly diag ...... ional multiagent chemotherapy.
@en
P2093
Christopher R Heery
James E Herndon
James J Vredenburgh
Jeremy N Rich
Mary Lou Affronti
P304
P356
10.1002/CNCR.24398
P407
P577
2009-08-01T00:00:00Z